NCT05967689: A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
- State
- Under way
- Phase
- Phase 2
- People
- 220 planned
- Started
- 31 Jul 2023
- Primary completion
- 31 Aug 2028
- Arms
- Cohort A ("prior ex20ins treatment"), Cohort B ("first-line treatment"), Cohort C ("active brain mets"), Cohort D ("other uncommon EGFRmts")., Dose Optimization Substudy: Arm A, Dose Optimization Substudy: Arm B
- Results
- None posted
- 31 Jul 2023: Trial started
- 1 Aug 2023: Trial registered